P180 Results from an interim analysis of a recombinant human C1 inhibitor treatment registry in Europe

Hereditary angioedema (HAE) caused by C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent episodes of disabling swelling. Recombinant human C1 inhibitor (rhC1-INH) is approved for treatment of HAE attacks. A treatment registry was established in Europe to review the safety and efficacy of rhC1-INH.